we'll hear from gileasd on monday, amgen on wednesday and biogen on thursday. >> i'm looking at amgen. it's obviously one of the bigger one the. i'm going to put it in the context of the performance relative to other biotech. so here's a long-term chart and we're going to draw some lines. the first thing i would call your attention to, a two-panel chart. the stock itself. the bottom panel is relative performance of amgen to its peer group. even as basically we have stalled here, there's no progress, your relative performance, which is very, very important, has been consistently good. outperforming the ibb. and i think that's the beginning of your setup. now let's draw some lines. here's the long-term chart again. here's your wedge. it is this, it represents a debate, right, a series of lower highs, higher lows. you get into the apex, a wedge, and at some point the gavel comes down, the debate is won by the bearer of the bull and it looks like we're heading up and out here. so what i want to play for is the following. here's now let's zero into the immediate. this is the all-time high,

amgen is one.fizer is another. >> i like both to the upside. >> up next, your tweets in the final call from the opgs pits. i'm here at the td ameritrade trader offices. steve, other than making me move stuff, what are you working on? let me show you. okay. our thinkorswim trading platform aggregates all the options data you need in one place and lets you visualize that information for any options series. okay, cool. hang on a second. you can even see the anticipated range of a stock expecting earnings. impressive... what's up, tim. td ameritrade. the check they sent isn't enough to replace your totaled new car. the guy says they didn't make the mistake. you made the mistake. i beg your pardon? he says, you should have chosen full-car replacement. excuse me? let me be frank, he says. you picked the wrong insurance plan. no, i picked the wrong insurance company. with liberty mutual new car replacement™, we'll replace the full value of your car plus depreciation. call and if you have more than one lib

>> looking at amgen, one of the bigger ones.ant to put it in context of the performance relative to other biotech. so here's a long-term chart. we'll draw lines. the first thing that i would call your attention to is two-panel chart. the stock itself. the bottom panel is relative performance of amgen to its peer group. so even as basically we have stalled here, there's no progress, your relative performance which is very, very important has been consistently good. outperforming the ibb. i think that's the beginning of your setup. let's draw some lines. here's the long-term chart again. here's your wedge. you call anything. but it is this, it represents a debate. a series of lower highs, higher lows. you get into the apex, a wedge. at some point the gavel comes down, the debate is won by the bear or bull. it looks like we're heading up and out here. and so what i want to play for is the following. here's now at zero into the immediate all-time high, 181.81, here are the lines. there's our high. here are our lines. i think you're

last week mike and carter played amgen for a breakout.listen. >> i think you're going to punch out, come out through the tops and make a run for the high. >> if i was going to make a play for next few months, the simple way one could take advantage of this setup is to sell the october 1.65 put and collect $6.60 for that. >> the stock hit a 2016 high today. carter, still like the chart? >> it still should be a follow through situation. it's just getting going, moving above those tops. good stock, good results and technically looks good so want to stick with it. >> this is an interesting situation because now we've seen profits on short put. you can put 3 bucks in your pocket and if you want to press the long, that's approximately how much the october 1.75, 1.85 call spread cost right now. you could take your profits and put it on the call spread and at that point, you basically get a free ride to the houseside, playing with house money. >> every friday eastern time -- i'm not kidding around of the tune into the show. you get trades like th

good quarter for amgen. one thing they are highlighting is that the beat may have been driven by price increases, particularly enbrel, rather than increase demand across the board. that maybe why you're saying shares down slightly. the call is going on now. it's during commentary. in the q and a, we expect the hear questions about the new cholesterol drug as well as competition for bio similars, these generic versions of bio logic drugs. finally, there's going to be questions about m&a, engine's got a loft cash. bio tech value vegasyigss f sma companies are down. and of course, we got news yesterday from third point that they have sold out of their amgen state. they've sold out of this complete stake because we saw bert opportunities elsewhere. that the commentary across the board for big bio techs right now. >> thanks. >> meg, stay with us. >> i'm wondering, they were able to increase price, but doesn't seem to matter for the stock. do you think we'll see that more broadly in the space? >> good question. th

amgen hasn't sloan as much as others.his report looks pretty good versus expectations which were quite a bit higher than the work on the street. >> anything to add there, tim? >> for a lot of these names, amgen is one where the earnings model is well established. i think the pipeline is fine but i think the valuation isn't quite as cheap as other players. i think people are probably, they say neutral. haven't heard detail of this report. but i don't think there is anything here to tell us that will change that view. >> all right. turning back to the markets, talking about the fed, the impact the fed's decision did or didn't have, and we get european stress test. bank stress test tomorrow. it seems like there is a lot international force and maybe that's why it comes back to the dollar. >> it is interesting because it was the european banking sector that banked u.s. stocks and there were compounding effective of the fed having jumped and volatility coming out of china and a hard landing or slowing growth there. a lot more

amgen and facebook. so a little bit to talk about there. last night it was all about apple. the stock surging after the company said it sold more iphones than wall street had expected. in the third quarter also offering revenue outlook for the current quarter that is better than most analysts estimated hoping to ease some concerns apple had hit a wall. marketing the first time in ten quarters the company has seen revenue growth in ipad sells. talking about the performance with an analyst in just a couple of minutes. take a look at the futures right now. not only do we have the earnings report. we had twitter last night. right now things looking up on the high side. dow would open higher. s&p 500 about 3.5. nasdaq up close to 30 points this morning. >> the apple stuff makes a lot more sense to me, andrew, because when we were talking about when they were still growing. >> yes. >> they were going to grow from a revenue base quarterly of like

>> yeah, well, you know, amgen has been sort of a tweener, trading sort of flat. i think the key is that as money comes sbook biotech, in sis a laggard in biotech. we can move higher. i think, again, good earnings this week would be the one that sets the tone. i think i've got more confidence on amgen's numbers this year than any of the our four biopics. confident in the guidance. >> a great point. interest rates. sensitivity to the sector. explain that and your expectation going forward? >> the nonprofitable bio techs that they are capital use egg. cost of capital goes up, they go down. access to capital goes down, too. not the big guys, like the celgenes but the small caps, making up a lot of the nasdaq index will go down. just make the point that we say the heck with biotechs anyway and own some of the med devices like boston scientific and hmos like united. if you really wanted to be in biotech own the real estate, the reit that owns the property underneath the biotechs and don't have to worry about pipelining and get yield. >> thanks for coming out. >> thank

amgen 81 dollars in august. a year ago since that peak, as it has gone down on an absolute basis, it has outperformed the ibb and that is very important. meaning it's a defensive name within a fairly aggressive group. and i think that is going to serve you well if one were to do this trade. here is the actual chart itself on the long-term basis. you can draw the lines any way you want. my eye sees that and i think we are going to resolve this. keep in mind that when you have a standoff. bears and bulls are very much matched off. a series of high or lows or highs or lows. many people bet it's going to do this and that makes a market. i take the other side. i think the uptrade is coming based on how good the relative performance has been. i want to zero in on this long-term wedge more immediately. here is base of the action of the past year and a half. here is our all-time high. 181. again, let's draw some lines. so no lines. lines. i think we are going to do it. i'm going to play for the past high. 181. sort of a

engi amgen peeked a year ago in august. since that peak, it's out performed the ibb and that's very important. meaning, it's a defensive a fai group. here is the actual chart itself on the long-term basis. again you can draw is the lines any way you want. my eye sees that. when you have a standoff. bears and bulls are very much matched off. a series of low or highs. people make the bet this is going to do this and that's what makes a market. i'll take the other side of that. i think the uptrade the coming based on how good the relative performance has been. soy want to zero in on this long-term wedge more immediately. here is base of the action of the past year and a half. here's our all-time high. went to about 17.81. let's draw some lines. no lines, lines. i think we're going to do it. i'm going to play for the past high at 181. sort of an offensive, defensive low beta name. >> that would be quite some upside. >> i do think we're in a world right now where it's hard to imagine what it will good nudes for a news for any st

amgen and facebook. so a little bit to talk about there. last night it was all about apple.er the company said it sold more iphones than wall street had expected. in the third quarter also offering revenue outlook for the current quarter that is better than most analysts estimated

look at the big four biotechs, amgen, biogen, celgene and gilead.he people expect that pressure to continue and all this focus on drug pricing, we also have seen some unsuccessful clinical trials recently. beginning of june we saw d disappointments that hurt sentiment across the sector all around. then of course concerns about slowing growth in some of the biggest names like gilead and biogen with franchises in multiple sclerosis and hepatitis c. the election is basically going to continue as it has been. people are hoping maybe there will be some focus less on drug pricing, essentially that's when people are setting aside we are going to have earnings and people are waiting to see what we'll hear from the biggest names. july 21st we hear from biogen and celgene. these companies have a lot of cash and people wonder do they have to buy in order to get growth. and of course data. that is one of the biggest catalysts across the sector. people waiting for eli li lilly in the fall. alexion their big drug which disappointed, later this week they'll presen

. >> i like amgen long side. health care. >> mike. >> enjoy independence day weekend.f you're trying to catch lobsters as i have been, don't try to disguise yourself as one first. it's not working for me. >> meaning wear sunscreen. >> brexit or not, that was never part of my thesis for bearish banks here and i think something's going on with the european banks here. i think you can look to express that in european banks. >> i'm melissa lee. thanks so much for watching. pr more, check out the website. have a great fourth of july weekend. enjoy your weekend. "mad money with jim cramer" starts right now. >>> pie my mission is simple, to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere, and i've promised to help you find it. "mad money" tastarts now. >>> hey, i'm cramer. a lot of people want to make friends, i'm just trying to make you some money. call me at 1-800-743-cnbc or tweet me @jim cramer. the next time you feel like

they voted it's similar to one made my amgen's rival, but it's percent. >>> there is now yet another online threat to your security. it is growing rapidly, targeting people in places you might not expect. it is called ransom wear. what hacl valuable information on your computer and then literally hold it for ransom. demanding you pay them to give you your information back. naturally expect banks, hospitals, even the rich and famous to be the obvious. when andrade found in a recent target is an unusual one. a nascar team. >> an up and coming nascar team just days away from the big race. when the crew chief's laptop encontributed. >> his criti files locked up. the team had been hit with the virus. it kidnaps the data while criminals hold it for ransom. and the panic is r the fbi, a a like this are skyrockets. with law enforcement virtually powerless to stop millions and millions of dollars. have been lost. and more will be lost. >> special agent will bals man fanlgs the investigations nationwide. he says wh throu an e-mail attachment. >> once you've opened the attachment, your computer

before it was amgen.s big. >> really early. >> we definitely are early -- >> you're very early. and amgen was just a molecule. that's one -- and it did. it went from $1 a share to $1,000 a share. >> it was the first biologic. >> i know. how far off are you talking about a transplantable organ that would be commercially available? at least a decade, right? >> i think it's less than a decade. we'll have the first organs in patients before the end of this decade. before the end of 2019. so i would say, you know, fda approvable around 2023. >> you're working with the best innovators in the world. working on even 3d printed organs? >> well 3d printed scaffold for the organ which is kind of the skeleton for the organ. then we cellularize that. so there's no rejection whatsoever. >> we got to go. you want to weigh in on the election, ten seconds? >> no. >> no? smart woman. >> easy out. >> for purposes of innovation, you have a candidate? >> i really -- i focus on our shareholders, our company. my candidate is sc

stocks go lower, not higher in that environment. >> you mentioned dividends and amgen. does it make her sense that can go after a company that can boost the dividend, or paying out, 3, 4r, 5. if given a choice between the two, would prefer to have dividend growth over time. the swap market is implying a less than 2% annualized dividend growth for the next ten years. my forecast is 4% dividend growth so that increased rate of dividend growth leads to a gently rising market. >> do you think they've reached on campbells and all of those. >> it's a concern broadly across the market and essential in some areas that you mentioned. preference would be for telecom, we get high dividend yield and relatively less highly valued stocks. some of the consassumumer discorrectionary presidents, as well. >> david kostin of goldman sachs. >>> just lost 18,300, and other indices in the positive as you can see in the wake of the payroll, and all the details we got from david. coming up, amazon is hitting an all-time high today, as its prime day kicks off. we'll break down what it means for

. >> health casework an interest in pfizer and amgen. >> so you won't need to buy gold bond powder if you treat your body properly. i've really enjoyed being with you guys. it's a tough show to do. looks like our time has ek >>> my mission is simple. to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere, and i promise to help you find it. "mad money" starts now! >>> hey, i'm cramer. welcome to "mad money." welcome to cramerica. other people want to make friends. i just want to make you some money. my job is not just to entertain you but to educate you. so call me at 1-800-743-cnbc. you thought we done with earnings. forget about it. sure, we have vulcan materials kicking things off on monday, and this maker of aggregates, also known as stone, is going to tell a pretty good story. vulcan does well when there is construction in the company and highway billsening pa ebeing pa. right now we have both. and then we go to caterpillar, because construction is booming. i know that many of you at home are hungry for yield. which is why

jim, with a $4 dividend does amgen have room to run? >> the out look, stocks are in good shape.ra in illinois. >> chicago cubs. >> yeah. big changes. >> yeah. question about westar energy. >> sell. i feel strongly that is a better one. robert in nevada. robert. >> booya from sin city. >> nice. >> wynn resorts, plans of changing the golf course into more hotel space and a lagoon. >> wynn is flying. they report this week. i am a believer of steve wynn. and that is the conclusion of the lightning round. >> the lightning round is sponsored by td ameritrade. you know that thinkorswim seamlessly syncs across all your devices, right? oh, so my custom studies will go with me? anywhere you want to go! the market's hot! sync your platform on any device with thinkorswim. only at td ameritrade will your business be ready when growth presents itself? american express open cards can help you take on a new job, or fill a big order or expand your office and take on whatever comes next. find out how american express cards and services can help prepare you for growth at open.com. great time for a

amgen. >> you're both on the same one. >> yeah. >> okay. okay. no pressure to be different then. dan. >> hyg. it sets up for a good risk/reward. >> on the basis that? >> that options are >>> my mission is simple. to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere, and i promise to help you find it. "mad money" starts now! >>> hey, i'm cramer. welcome to "mad money." my job is not just to entertain you but to educate and teach you, so call me at 1-800-743-cnbc or tweet me @jimcramer. ah-oh, this is it. the week i am truly dreading is upon us. the one where you're up all night, studying the evening earnings reports, or if you're like me, you hire someone to sleep for you during this period, only to fall behind terribly in the morning conference calls. this is the week where there's so much confusion. so much cacalf any of sound that the market stumbles under its own weight. that's why you should have cash going into next week. we've told the club that subscribes to the newsletter, raise some quash. some things occur duri

amgen. the company is reporting today after the close.tors are looking for onusted earnings of $2.74 $5.8 billion. another company that has beaten eight out of the eight last -- would not be surprised to see this company beat once again, driven by cost-cutting plus strength in the chronic disease drug. the biggest member waiting for the nasdaq biotech index, and when we going to the bloomberg and take a look at the one-year chart of the biotech index, we see a brutal bear market, down 40%. over the last few days, we have seen that the biotech index is starting to peak above the trendline, suggesting that perhaps we are starting to see the early signs of a reversal. for viewers who would like to take a look at that chart, they can do so by going into the 2336.erg g #btv i love those charts, amanda. amanda: i love those two. abigail doolittle, thanks. joe: the time could soon be coming for the fed to ask. inflation measures have been slowly converging on the fed's 2% goal. we are looking at the chart of three months and one-month annualized

the way all these guys trade right now, look at amgen yesterday.ut out these great numbers, but it ran into the number. the stock pulls back. when you're talking about gileads, we've had some huge movement in some of these biotechs. when you look at bristol meyer, it is much more like a biotech, scott, than it is a pharma name. so because of that, it's going to be a little bit more volatile. >> i just wanted to say, on bristol myers, and some of the other health care names, where they're very expensive drugs, you have to be careful that they don't run into a political pushback. >> well, they already have. gold prices hitting a two-week high in today's session. we'll talk about that when we come back in two minutes. alk abs on their auto insurance. wouldn't a deal involve two parties discussing something? a little give, a little take. because last time you checked, your rate was just whatever they say it is. why not give you some say in the matter? or even better, let your driving do the talking. liberty mutual righttrack® finally puts you in contro

a couple things i want to point out though, essentially third point as eliminated the position in amgen, not seeing a heck of a lot movement in that stock after hours. but we'll see what happens tomorrow. they remain iffaler again. during the quarter, the top winners were baxter international which has been up nicely. the republic of argentina, chesapeake energy, california resources and an unnamed pharmaceutical short. they talk at some length about baxter which they really like for a whole host of reasons. they're expecting higher value obviously and the stock going forward. they've been involved with it for multiple quarters now. and they just said that essentially it's very important to have a geo political outlook in this particular market. that positioning is really key as key as stock picking. that crowdedness and factor risks are problems that are significant now in a way that they have not been in the past. finally this is interesting. they think that energy prices bottomed out in february and right now they have a $1 billion long portfolio in energy primarily through credit. a

this is the best chart in biotech right now, broke out definitively, amgen, the reaction last quarteras negative. didn't take long to come back. but they are, i think, poised to be the next jnj move. >> somebody give me ten seconds on whole foods. >> steve. >> crickets. that's it. no one has a feel? >> no, look, the story's been coming back but the competition's been increasing. i don't think you make a bet on this. >> my dentist over here. goodness gracious. >> sully's ears popped up. >> my ears always pop up. >> teeth cleaning tomorrow at noon. >> sully's ears popped up, that's not news. >> wow. >> that's just not right. >>> that is wrong and it ain't right either, guys. thank you. welcome to this fed day edition of "power lunch." we are less than an hour away from interest calls. could the fed shock us all and raise rates or signal a hike coming in september? the market not expecting it, but that's exactly what makes it interesting. we have an all-star task force to

. >> i would just say that ibb and some of the big players, celgene and amgen, all underperformed. 240that's the level. bounced off there three times and you can probably trade against that from the long side rather than having the idiosyncratic risk and i know juno is not a big market cap and celgene owns 10% of that and deflates a little bit. looking to pick up exposure, maybe it's the ibb or using a 240 stock. >> jump back in on that call. should be an interesting trading day for juno. meg tirrell, our biotech reporter. >>> up next, energy seeing a big run today despite this year's runoff and one group of stocks is noticeably sitting out the moves. later media meual on stars. julia boorstin has a report just after this. hats for cats. everyone said i was crazy. when i went online. i got my domain, catswithhats.com from godaddy. now these things are fee-ly-in'utta here. t a crazidea youhink you can turn into a success? we know you can and we've got a domain for you. go you. godaddy. (sakjapanese) oh watson, yr japanese is very good. thank you. (speakinjapane) exactly. i can understan

amgen tops estimates. that stock basically unchanged. >>> cheesecake tractfactory repg better than expected profit. still upping stock buyback plan. up about 1.5%. >> we have more here. groupon. is that going to be around? >> we are going to talk to the ceo and i suspect he will tell you he plans to be around. >> it was 25, 25 dollar stock once so it's up today. is it are a real. >> it's a real company. >> i bet the $6 billion offer they got from google a few years ago is pretty good right now. >> let's talk about alphabet. google now is a verb. it's probably known in every language. then there was another one that decided -- changes the name. and totally ruins years. p when you say alphabet, i know it's google, but google. why don't you do it some other way. keep it as google. it's google. alphabet. >> the company hasn't even rebranded from the top down. >> you can't rebrand the alphabet. stop. go back. >> it's still the google table. >> new coke was a mistake. admit it and go back. >> you think alphabet

amgen, similar picture in 2016, nothing. j.p.organ chase, they've decided not to give to the conventions this year, but they are donating to charities in the cities where the conventions are being held to help the communities there. also, ford, motorola solutions and u.p.s. all giving $100,000 or more last time around, this time around zero, zero, zero across the board for all of those guys. again, different reasons for each company, but ultimately a decision not to participate in the political spectacle that is a national political convention. most of these companies are not contributing both here at the rnc and at the dnc in two weeks in philadelphia, guys. so just a whole pullback, generally, from politics is what we're seeing from corporate america. >> yeah, those numbers highlight it quite starkly. thanks. eamon, thanks. >>> managing to push the democratic party platform further to the left, more now from cnbc contributor larry kudlow also an informal advisor to the donald trump campaign. this is my favorite part in the camp

convention and work through the list, and discovered that some of those had sponsored back then, including amgen, general ,lectric, for, all said -- ford all are not doing it. they are also not doing it in philadelphia. google will be there. the american petroleum institute will be doing things. coca-cola. that is less of a group than in the past. they have been facing pressure group named color of change, say if you want to be associated with a party who has said such awful things about immigrants, women, banning muslims in the country, you go right ahead and you can anticipate a boycott from a lot of your would-be customers. a lot of these companies have seen pressure and want to stay away from the hot political gear it is, figuring it could be bad for business. >> your story points out the insurrection among delegates who do not want to see trump as the nominee. is there anything there? >> i do not know. what started as something that it could pick up steam, has fizzled. you have got a two-step process. this is an idea that would allow the delegates to them to vote their conscience instead of

lots of big names next week and amgen, merck.rs from every different sector and so far 68% of the earnings have been better than expectations. that's stronger than what we have seen historically. and then same thing for those that have reported lower than expected and stronger than what we have seen and then next week and that can all change. >> get ready for it. thanks. see you later. so yes. if we hold right here, we'll have a record by fractions. on the s&p as we go out for this friday. girls who code. sponsored by blackrock ringing the closing bell here at the new york stock exchange. and the motion picture and television engineers association ringing at the nasdaq. stay tuned now for hour two of "the closing bell." have a good weekend, kelly. >>> thank you, bill. welcome to "the cloudsing bell." i'm kelly evans. we are closing at record highs again on wall street. s&p 500 adding about 9 1/2 points. 2174 or so is the level there. half a percent. nasdaq also up half a percent today up 26 points. dow lagging a bit and added 51,

amgen up 14.5%.iogeun 21.3%. >>> zika virus was a source of concern for americans heading to rio de janeiro for the olympics but as of this morning, it is americans across the southern part of the country paying much closer attention. meg terrell with the latest on the spread. meg? >> that's right. today cdc and the florida department of health saying we have four cases of locally transmitted zika virus here in the united states via mosquito. this is the first local transmission in u.s. states by the mosquito and the cdc says throughout the summer months we could expect to see more cases. now, we do have the two mosquitos that transmit the zi covirus in the united states. you can see here we have a map. the one you see in blue there and then yellow, the main transmitter of the zika virus. we have seen the four cases in a very small area of miami. and of course, we have heard that president obama has been briefed on this situation. and he is, the white house still talking about the funding fight here.

we have facebook, amgen and whole foods. we'll preview the results coming up.r shares dropping now that athleisure market is slowing. a you're late for work. you grab your 10-gallon jug of coffee, and back out of the garage. right into your wife's car. with your wife watching. she forgives you... eventually. your insurance company, not so much. they say you only have their basic policy. don't basic policies cover basic accidents? of course, they say... as long as you pay extra for it. with a liberty mutual base policy, new car replacement comes standard. and for drivers with accident forgiveness, liberty mutual won't raise your rates due to your first accident. learn more by calling at liberty mutual, every policy is personal, with coverage and deductibles, customized just for you. which is why we don't offer any off-the-shelf policies. switch to liberty mutual and you could save up to $509. call liberty mutual for a free quote today at see car insurance in a whole new light. liberty mutual insurance. a. >>> under armour plans to move into the fao schwartz loca

an fda panel has approved amgen's version of the drug humera which has brought in millions of dollarsive alternative. the maker of humera is trying to block the drug from reaching the market. >>> you will soon be able to read nutritional information on beer. the beer institute says a number of big companies, including anheiser-busch and miller/coors have agreed to start voluntarily listing calories, carbs, protein, fat and volume by volume on nutrition labels. consumers should start seeing some labels on products right away and hope all of members will be using labels by 2020. >>> trip advisor offering something new for its travelers in addition to reviewing hotels, restaurants and attractions, trip advisor users can now review airlines. they can rate an airline based on leg room, seat comfort, customer service, check-in, boarding and value. it is aimed at giving consumers a better way to compare and shot for flights. >>> and nissan now showing off its new technology aimed at helping drivers not exactly a self-driving car just yet. pro pilot though technology puts a camera an the rear